PTC Therapeutics(PTCT)
Focus: PTC Therapeutics is a publicly traded biotech company developing small molecules and gene therapies for rare genetic and neurological diseases, with commercial scale anchored by the corticosteroid deflazacort (EMFLAZA) for Duchenne muscular dystrophy.
Profile data last refreshed 18h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
16
Should You Work at PTC Therapeutics?
AI assessmentPTC is a high-risk, high-reward mid-cap with strong science and cash position but critical near-term patent cliff dependency—suitable for risk-tolerant professionals seeking rare disease expertise.
Why Work Here
- Diversified pipeline with 20 active programs spanning Phase 2–3, including multiple shots on goal in DMD, cystic fibrosis, phenylketonuria, and inherited mitochondrial disease.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$938M
Key Products
$15M Part DDeclining
Peak
Help build intelligence for PTC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.